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Abstract There is an urgent need for effective pharma-
cological therapies to help tackle the growing obesity
epidemic and the healthcare crisis it poses. The past
3 years have seen approval of a number of novel anti-
obesity drugs. The majority of these influence hypotha-
lamic appetite pathways via dopaminergic or serotoniner-
gic signalling. Some are combination therapies, allowing
lower doses to minimize the potential for off-target effects.
An alternative approach is to mimic endogenous satiety
signals using long-lasting forms of peripheral appetite-
suppressing hormones. There is also considerable interest
in targeting thermogenesis by brown adipose tissue to in-
crease resting energy expenditure. Obesity pharma-
cotherapy has seen several false dawns, but improved
understanding of the pathways regulating energy balance,
and better-designed trials, give many greater confidence
that recently approved agents will be both efficacious and
safe. Nevertheless, a number of issues from preclinical and
clinical development continue to attract debate, and addi-
tional large-scale trials are still required to address areas of
uncertainty.
Key Points
For the first time in over a decade, several new drugs
have been licensed for long-term weight
management.
Weight reduction can be achieved pharmacologically
by reducing appetite, increasing energy expenditure
or both.
Improved understanding of energy homeostasis has
provided novel therapeutic targets.
1 Introduction
The increasingglobal prevalenceof obesity threatens to reverse
the improvements in life expectancy seen over the past several
decades. Currently, 600 million adults, 13 % of the global
population, are obese, defined as having a body mass index
(BMI) of C30 kg/m2 [1]. A substantial increase in childhood
obesity is a particular cause for concern, as childhood BMI
often persists into adulthood [2, 3]. Current projections an-
ticipate that 20 % of adults will be obese by 2030 [4].
Obesity increases the risk of cardiometabolic disease,
dementia, kidney disease, cancer, respiratory disease and
osteoarthritis. This presents enormous healthcare chal-
lenges for the future. Preventative measures to tackle en-
vironmental determinants of obesity on a population level
are essential, but so far they have been insufficiently ap-
plied to reverse the trend. Effective treatments for indi-
viduals are therefore urgently required. Lifestyle
interventions can be effective, but inadequate responses are
seen in a significant proportion of patients. Despite the
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gold-standard programme used in the Look AHEAD trial,
only 46 % of patients achieved 5 % weight loss [5]. Fur-
thermore, weight regain is common when the intensive
aspect of lifestyle programmes finishes [6]. Bariatric sur-
gery leads to sustained weight loss and long-term health
benefits [7] but carries with it a small but significant pe-
rioperative mortality rate and a risk of long-term compli-
cations, and many patients choose not to undergo an
invasive procedure to help them lose weight.
There is therefore a clear incentive to develop effective
pharmacological treatments to aid weight loss. In this re-
view, we summarize the physiology of energy homeostasis
to reveal pharmacological targets for weight reduction,
before discussing past and current treatments, novel agents
in the pipeline, the regulatory hurdles they face and their
position in the overall management of obesity.
2 Strategies for Pharmacological Weight Loss
Environment, behaviour and genetic traits all influence
body weight. The final common pathway for each of these
disparate factors, however, is changes in energy intake or
energy expenditure. Obesity results from energy imbalance
sustained over several years, and obesity treatments can
work only by reversing this. Accordingly, all anti-obesity
agents have at least one of the following effects:
1. Reduce food intake or nutrient absorption.
2. Increase resting or activity-related energy expenditure.
Appetite reduction is the primary weight loss mechan-
ism for the majority of current agents. The arcuate nucleus
of the hypothalamus plays a critical role in appetite
regulation (see Fig. 1). It contains two key populations of
neurons, which project to other hypothalamic nuclei and
distant brain regions to alter feeding behaviour—one co-
expresses agouti-related peptide (AgRP) and neuropeptide
Y (NPY), which increase food intake, and the other co-
expresses pro-opiomelanocortin (POMC) and cocaine- and
amphetamine-regulated transcript (CART), which inhibit
food intake. Because of the semipermeable blood–brain
barrier in this region, peripheral signals indicative of en-
ergy balance—including glucose, insulin, leptin, a number
of gut-derived factors including glucagon-like peptide-1
(GLP-1), peptide YY (PYY), oxyntomodulin and ghrelin—
can directly interact with these neurons and influence
feeding behaviour [8]. POMC neuronal activity is also
modulated by dopaminergic and serotoninergic signalling
from other brain regions and is therefore affected by a
number of central nervous system (CNS) drugs that act on
these neurotransmitters [9–11]. Of course, appetite is
regulated not just by physiological energy status but also
by environmental and emotional cues, such as the sight and
smell of food. These reward-associated stimuli are inte-
grated by the mesocorticolimbic reward system, with
dopaminergic neurons originating in the ventral tegmental
area (VTA) projecting to the nucleus accumbens and the
prefrontal cortex, where they influence feeding behaviour
[12]. Modulation of signalling in the dopaminergic reward
system is also suggested as an additional mechanism for
the action of some appetite suppressants [13, 14].
Interest has surged over recent years regarding the po-
tential to increase resting energy expenditure by pharmaco-
logical activation of brown adipose tissue (BAT) [15]. Well
known as a source of non-shivering thermogenesis in human
infants, it was assumed not to persist into adulthood, until
review of positron emission tomography (PET) images from
adult cancer patients revealed extensive glucose-avid areas
in the neck and thorax, subsequently identified as brown fat
[16, 17]. BAT expresses high levels of uncoupling protein-1
(UCP-1), which uncouples mitochondrial substrate utiliza-
tion fromATP production, causing energywastage [18]. The
best-known activator ofBAT activity is cold exposure; under
thermoneutral conditions, human BAT is unlikely to play a
significant role in energy homeostasis. Nevertheless, a va-
riety of peripheral factors directly increase BAT activity,
such as catecholamines, thyroid hormone, glucagon and fi-
broblast growth factor-21 (FGF-21) [19], raising the possi-
bility of pharmacological manipulation. Furthermore,
AgRP/NPY and POMC neurons control sympathetic inner-
vation of BAT, revealing a central role for this system in
various aspects of energy homeostasis [20–22]. This is
relevant from a therapeutic point of view, as compensatory
physiological and behavioural responses limit the weight
BAT acvity Food intake
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Fig. 1 Simplified schematic of hypothalamic energy regulatory
pathways. Other pathways, including the reward circuitry, are
involved in appetite and energy expenditure, but an understanding
of the central role of the hypothalamus is useful in order to appreciate
the mechanisms of action of several weight loss agents. AgRP agouti-
related peptide, BAT brown adipose tissue, CART cocaine- and
amphetamine-regulated transcript, GLP-1 glucagon-like peptide-1,
NPY neuropeptide Y, POMC pro-opiomelanocortin, PYY peptide YY
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loss that is achievable by any one mechanism [23]. Conse-
quently, treatments that target both sides of the energy
equation have the potential for greater effectiveness [24, 25].
Some studies have hinted at a possible minor role for BAT in
mediating the effects of some newer anti-obesity agents [26,
27], but its current status is primarily as an area of active
research with potential future therapeutic application.
3 How Are Weight Loss Drugs Judged?
For most obese patients, losing enough weight to return to a
‘normal’ BMI is unrealistic, even with bariatric surgery.
Instead, the focus should be on health benefits resulting
from more modest weight loss. A reduction in body weight
of 5–10 % is enough for significant improvements in car-
diovascular risk factor profiles [28–32], kidney disease [33]
and osteoarthritis [34]. Consequently, the 5 % weight loss
threshold features prominently in the current US Food and
Drug Administration (FDA) and European Medicines
Agency (EMA) guidances for approval of weight man-
agement drugs [35, 36]. While the absolute proportions of
patients achieving this degree of weight loss in clinical
trials are an important metric for regulatory bodies, dif-
ferences in lifestyle programmes between trials can make
comparisons difficult. Therefore, 5 % weight loss remains
a useful target in clinical practice, but, in this review, we
focus on average placebo-subtracted percentage body
weight reduction as the key indicator of weight loss effi-
cacy. Nevertheless, inferring positive health outcomes
purely from weight loss is ill advised, as shown by the post-
approval withdrawal of a number of agents—most recently,
sibutramine due to increases in major adverse cardiac
events [37]. All anti-obesity agents seeking regulatory
approval now require pre-specified cardiovascular safety
data as a minimum; improvements in surrogate cardio-
vascular risk biomarkers are also considered favourably by
regulatory bodies.
4 A Brief History of Anti-Obesity
Pharmacotherapy
In spite of a potentially lucrative market for effective
pharmacological treatments for obesity, at the end of the
2000s, just one agent (orlistat) was approved for long-term
use in North America and Europe. This reflected not any
difficulty in producing drugs that caused weight loss, but
concerns about safety, which, in many cases, were high-
lighted only after the drugs were brought to market. In the
first half of the last century, popular ‘diet pills’, such as
thyroxine and the respiratory chain uncoupler 2,4-dinitro-
phenol, were effective in producing weight loss but
exposed users to thyrotoxicosis and potentially fatal hy-
perthermia, respectively [38]. Subsequently, amphetamine-
mimetic anorectic agents, such as desoxyephredine and
diethylproprion, which enhance norepinephrine and
dopaminergic stimulation of anorexogenic POMC neurons,
enjoyed several years of popularity before the perceived
addiction risk led to changes in their licences to allow
short-term use only. However, in 1992, a well-publicized
study demonstrated impressive results from combined use
of two of these older drugs, phentermine and fenfluramine
[39]. The ensuing ‘phen–fen craze’ came to an abrupt end
in 1997, when reports emerged of valvular abnormalities in
young patients taking these agents [40]. Shortly afterwards,
the FDA approved sibutramine, a serotonin–noradrenaline
reuptake inhibitor with an unimpressive antidepressant
action but a powerful anorectic effect [41]. Use of sibu-
tramine was terminated in Europe and the USA in 2010
after adverse cardiovascular outcomes were revealed in a
post-marketing study [37]. In this study, the risk was ob-
served only in patients with prior cardiovascular disease,
and not in those at high cardiovascular risk (due to dia-
betes) but without prior cardiovascular disease, but the
signal was sufficient for regulatory bodies to request
withdrawal from the market. The well-known role of the
endocannabinoid system in appetite was the target of the
cannabinoid-1 (CB1) receptor antagonist rimonibant [42],
licensed in Europe (but not in the USA) in 2006. The re-
alization that some patients suffered significant psychiatric
morbidity while taking this drug [43], including an in-
creased risk of suicide, led to its rapid withdrawal from the
market in 2008. In fact, the reason that FDA approval for
rimonibant had been refused related to a signal of increased
suicidality in the pre-marketing submission. However, the
endocannabinoid system may yet prove a viable target,
with non-CNS-penetrating forms of these agents believed
to be less likely to lead to psychiatric morbidity [44].
5 Anti-Obesity Agents in Current Use
In spite of an inauspicious history, the recognition of future
health crises posed by the obesity epidemic, and better
understanding of the physiological mechanisms underpin-
ning appetite and energy homeostasis, have driven sig-
nificant progress in the obesity pharmacotherapy field. The
past 4 years have seen approval of a number of new agents.
Not all have been met with universal acclaim though; two
agents (lorcaserin and phentermine/topiramate) have failed
to gain approval for use in Europe. In general, both the
FDA and EMA have recognized some uncertainties relat-
ing to safety and efficacy with the novel agents; however,
the FDA considered the risk to benefit balance acceptable
for specific issues to be addressed with post-marketing
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trials, whereas the EMA demanded that further data be
obtained prior to licensing.
5.1 Orlistat
The only survivor from the pre-2010 era is orlistat (mar-
keted as Xenical), an intestinally active lipase inhibitor,
which reduces absorption of fat by 30 % [45]. Pooled es-
timates from long-term studies indicate sustained weight
loss of 2.9 % over placebo when given at the standard dose
of 120 mg three times daily [46]. Reduced progression to
diabetes [47] and improved glycaemic control in patients
who already have diabetes [48] have also been noted. Fat
malabsorption can give rise to side effects, including oily
stools, faecal urgency and spotting if patients continue to
consume a diet rich in fat, but these can be avoided with
appropriate dietary restraint. Indeed, it is hypothesized that
the effectiveness of orlistat likely reflects enforced dietary
changes rather than a direct reduction in calorie absorption
[49].
5.2 Lorcaserin
In 2012, lorcaserin (Belviq) was the first new anti-obesity
agent to be granted an FDA licence for long-term weight
management. Like fenfluramine, lorcaserin stimulates 5-HT
(serotonin) receptors on anorectic POMCneurons.However,
it was developed as a selective agonist of the 5-HT2C receptor
to avoid 5-HT2B-mediated valvulopathies, which afflicted
the earlier agent. In phase 3 trials, lorcaserin achieved av-
erage weight loss of 3.0–3.6 % better than placebo [50, 51],
with 2.3 times as many patients losing at least 5 % body
weight in the treatment groups. Glycaemic improvements to
the tune of a 0.5 % reduction in glycosylated haemoglobin
(HbA1c) were seen in patients with type 2 diabetes [52].
Lorcaserin is well tolerated by most patients, with few
withdrawals during phase 3 trials due to adverse events. It is
currently not clear, however, whether long-term use of lor-
caserin has the potential to cause valve abnormalities, de-
spite selectivity for 5-HT2C receptors. Pooled
echocardiographic data from 5249 trial participants indi-
cated a non–statistically significant risk ratio of 1.16 (95 %
confidence interval [CI] 0.81–1.67) for incident valvulopa-
thy [53]. A post-marketing clinical trial of major adverse
cardiac events, including valvular assessment, is intended to
answer this question more conclusively. The results of this
study might, however, come too late for lorcaserin to be
licensed in Europe. The manufacturer withdrew its applica-
tion in 2013 when it became clear that it would be unable to
address the safety concerns expressed by the EMA, which
pertained to the potential for psychiatric morbidity, valvu-
lopathy and carcinogenesis.
5.3 Phentermine/Topiramate
Soon after lorcaserin was licensed, the FDA approved a
second anti-obesity agent for long-term use: a fixed dose
combination of phentermine and topiramate extended re-
lease (marketed as Qsymia). Individually, these agents
were already marketed for different indications and at
higher doses, as a short-term adjunct for weight loss
(phentermine) and for epilepsy and migraine (topiramate).
As a centrally acting appetite suppressant with a mode of
action similar to that of amphetamine, phentermine’s short-
term-only license reflected concerns regarding the potential
for addiction [54]. Weight-lowering properties of topira-
mate had been noted in its initial trials as an antiseizure
agent [55], but dose-limiting neuropsychiatric effects pre-
cluded its further development as an obesity monotherapy.
The mechanism for topiramate-induced weight loss may
involve both inhibition of orexigenic glutamate signalling
[56] and increased energy utilization [57]. Combining
different weight loss agents with different mechanisms of
action is appealing for two reasons: first, it is less likely to
be hindered by redundancy and compensation in appetite
regulatory pathways; and second, it enables each compo-
nent to be given at lower dose to reduce side effects.
Weight loss data for phentermine/topiramate are impres-
sive, with a placebo-subtracted body weight reduction of
6.6 % at the approved dose of 7.5 mg phentermine/46 mg
topiramate [58]. Modest reductions in systolic and diastolic
blood pressure of 2.3 and 0.7 mmHg, respectively, were
also observed. A higher dose of 15 mg phentermine/92 mg
topiramate showed enhanced weight lowering of 9.3 %
better than placebo [59], but it is only recommended in
selected patients who lose insufficient weight on the stan-
dard dose, because of increased adverse effects, including
paraesthesia, dizziness, altered taste sensation, insomnia,
constipation and xerostomia. In clinical practice, titration
from an initial dose of 3.75 mg phentermine/23 mg topi-
ramate is employed to limit side effects. However, safety
concerns, particularly with regard to teratogenicity, neu-
ropsychiatric morbidity and cardiovascular effects, have
not been addressed to the satisfaction of the EMA, which
has refused to grant a license for use of Qsymia in Europe.
Some of the safety worries reflected previous experience
with higher doses of the individual components of Qsymia
rather than direct evidence of harm from trial data,
although some signals were present at the 15/92 dose, in-
cluding elevated heart rate and depression. On the same
evidence, the FDA took the view that careful prescribing
measures and ongoing patient monitoring were adequate to
sway the risk to benefit balance in favour of Qsymia. These
include, in particular, a risk evaluation mitigation strategy
(REMS) for the teratogenic potential of topiramate,
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requiring adequate contraception and regular pregnancy
testing for ongoing use.
5.4 Bupropion/Naltrexone
A second combination therapy, consisting of bupropion
and naltrexone (marketed as Contrave in the USA; ap-
proved name Mysimba in Europe), gained FDA and EMA
approval in 2014 and 2015, respectively. Again, these
agents were repurposed from existing indications. Bupro-
pion, an aminoketone which acts as a mixed dopamine/
norepinephrine reuptake inhibitor [60], is used as an an-
tidepressant and in smoking cession, and has previously
been evaluated as monotherapy in the treatment of obesity
[61]. Naltrexone is an opioid receptor antagonist, which is
used to treat alcohol dependence, reducing cravings by
inhibiting the action of b-endorphins on dopaminergic re-
ward pathways [62]. Combining these two agents leads to
enhanced appetite reduction, as bupropion stimulates
POMC neurons and naltrexone counteracts the autoin-
hibitory effects of endogenous opioids they secrete [63].
Data from phase 3 trials have indicated 3.2–5.2 % greater
weight loss at 1 year over placebo [64–67], with an asso-
ciated 0.5 % HbA1c advantage in patients with type 2
diabetes. Interestingly, despite superior weight loss in the
treatment groups, blood pressure reductions were actually
better in the placebo groups, suggesting a treatment-related
blood pressure increase. Indeed, concerns regarding car-
diovascular safety were the primary reason why approval
was not granted following the initial application in 2010.
However, interim analysis of a subsequent cardiovascular
outcomes trial provided reassurance for the regulatory
bodies. Hypertension should nonetheless be controlled
before treatment is initiated, and blood pressure should be
carefully monitored thereafter, particularly in the first
3 months, when an adverse response is most likely to oc-
cur. When bupropion is used as monotherapy for depres-
sion or smoking cessation, it carries a black box warning
stating the potential for increased suicidality. While there
was no signal of psychiatric adverse events in the bupro-
pion/naltrexone trials, the same boxed warning is included,
and patients should be carefully monitored to ensure these
do not develop.
5.5 Liraglutide
Liraglutide is the first of the GLP-1 mimetics to be granted
an obesity indication (as Saxenda). GLP-1 is an endoge-
nous incretin, released by intestinal L cells in response to
nutrient ingestion, which enhances glucose-stimulated in-
sulin release by pancreatic b cells and acts on satiety
pathways, including hypothalamic POMC neurons, to re-
duce food intake [68]. A possible role for GLP-1 in
stimulating energy utilization via BAT [27] requires further
investigation. Several analogues of GLP-1 are already
marketed for type 2 diabetes, where their anorectic effect is
well established [69]. A higher dose of liraglutide (3 mg,
versus 1.8 mg for type 2 diabetes) led to treatment-related
weight loss of 6 % over placebo [70]. Additional as-yet
unpublished phase 3 data submitted by the manufacturer
indicated 4.0–5.4 % weight loss over and above placebo at
1 year with liraglutide 3 mg [71]. As expected from its
pharmacology, significant improvements in glycaemic
control for patients with type 2 diabetes were noted (0.9 %
reduction in HbA1c), associated with improvements in
measures of both b cell function and insulin resistance.
Like other GLP-1 agents [72, 73], liraglutide increases
heart rate, an observation that has not been satisfactorily
explained, but evidence suggests it is not associated with
an increase in arrhythmias or hypertension. The question of
whether GLP-1-based agents can increase the risk of pan-
creatitis has attracted considerable debate [74–77]. The
increased rate of pancreatitis in diabetes and obesity [78],
as well as the inherent risk of over-reporting in pharmaco-
epidemiological studies, makes it difficult to unequivocally
identify a treatment-related adverse effect. In 2014, the
FDA and EMA concluded that assertions of a causal link
between incretin use and pancreatic pathology were in-
consistent with current data [79]. Nevertheless, an imbal-
ance in the incidence of pancreatitis (but not pancreatic
cancer) was noted in the liraglutide weight management
trials; the small numbers (2.4 versus 0.6 per 1000 patient
years) make it difficult to draw conclusions about causality,
but larger trials must be performed to address this impor-
tant question. Furthermore, Saxenda, like other GLP-1 re-
ceptor agonists, carries a boxed warning regarding a
possible risk of medullary thyroid cancer. This stems from
preclinical studies in which an excess of medullary thyroid
cancer and C cell hyperplasia was noted in rodents [80]; to
date, there has been no evidence suggesting this is also a
human phenomenon.
6 Likely Future Developments
The recognition of persistence of thermogenic BAT into
adulthood has led to intense interest in possible ways to
exploit this pharmacologically. Beyond cold exposure,
sympathetic activity is the best-known activator of BAT;
pheochromocytoma patients have extensive BAT deposits
[81]. To be useful clinically, a sympathomimetic agent
would need to be relatively specific for BAT to avoid
cardiovascular sequelae. The most promising target might
therefore be the b3 adrenoreceptor, which is expressed at
high levels in BAT [82], although it is also found in white
adipose tissue, the gastrointestinal tract, prostate and
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bladder [83, 84]. A b3 agonist, mirabegron, was recently
found to stimulate energy expenditure in humans [85]. In
this case, however, increases in heart rate and blood pres-
sure were noted, likely indicating action at other
adrenoreceptors. The success of this approach may there-
fore depend on generation of agents with better selectivity
for the b3 adrenoreceptor, or alternative methods of acti-
vating BAT. A further development is the possibility that a
subpopulation of white adipocytes have the potential to be
‘browned’, forming thermogenically active ‘beige’ adipose
tissue and increasing the capacity for therapeutic energy
wastage [86].
Another approach uses gut-derived peptides. As well as
GLP-1, the endogenous counterpart of liraglutide, several
other satiety hormones are released after a meal and trigger
cessation of food intake. Two of particular interest are PYY
and oxyntomodulin. PYY is a high-affinity agonist of the
Y2 receptor, which inhibits the activity of orexigenic
AgRP/NPY hypothalamic neurons [87]. Oxyntomodulin is
derived from the same precursor as both glucagon and
GLP-1, and is a dual agonist of both of these receptors [88,
89]. Administration of both of these peptides to humans
reduces food intake [90], and, in addition to this, oxynto-
modulin is able to stimulate energy expenditure, although
the receptor responsible for this effect is a matter of debate
[24, 91, 92]. Like GLP-1, both of these endogenous pep-
tides last for only minutes in the circulation because of
rapid enzymatic degradation, and their potential clinical
use as weight loss agents relies on the development of
long-lasting analogues. As enhancement of gut hormone
release is suggested as a possible mechanism for the large
weight reductions seen with Roux-en-Y gastric bypass,
combined use of two or more of these gut-derived peptides
has been suggested as a way to mimic the effect of bariatric
surgery without the need for a surgical procedure [49, 93].
7 The Position of Pharmacotherapy
in the Management of Obesity
Lifestyle measures are an essential part of any treatment
plan for obesity and provide health benefits independent of
weight loss. The best evidence for their effectiveness is
with intensive programmes addressing diet, activity and
behavioural factors [33, 94, 95]. The most powerful inter-
vention for weight loss is bariatric surgery, which leads to
an average 25–33 % body weight reduction, depending on
the surgical procedure. Bariatric surgery is superior to non-
surgical approaches with regard to weight loss and diabetes
remission, at least in the short-to-medium term [96].
However, patients are at risk of the usual surgical com-
plications, including perioperative death, anastomotic leak
and infection, as well as longer-term issues reflecting
altered gastrointestinal physiology, such as dumping syn-
drome, hypoglycaemia, micronutrient malabsorption and
cholelithiasis [97–99]. Resource implications and risks of
complications mean that surgery is generally restricted to
patients with a BMI C40 kg/m2, or C35 kg/m2 in those
with an obesity-associated comorbidity [100, 101].
For individuals who do not wish to undergo (or do not
meet the criteria for) bariatric surgery but are unable to lose
sufficient weight by lifestyle alone, pharmacotherapy is a
useful adjunct. Weight loss agents are generally licensed
for use in patients with a BMI C30 kg/m2, or C27–28 kg/
m2 in those with an obesity-associated comorbidity [102].
The choice of agent should reflect patient preference,
relative co-indications (such as diabetes for liraglutide) and
contraindications (such as seizure disorders for bupropion/
naltrexone), and relative efficacy (see Table 1). Weight
loss should be assessed at 3 months, and the treatment
should be discontinued or substituted if at least 5 % weight
loss has not been achieved.
In addition to surgery and pharmacotherapy, non-sur-
gical interventional procedures for obesity are an exciting
new development, which may widen options for weight
loss management in the future. For example, the En-
doBarrier system is an endoscopically inserted sleeve,
which replicates some aspects of Roux-en-Y gastric bypass
by accelerating nutrient delivery to the distal small in-
testine [103]. Implantable vagal nerve blockade devices are
designed to exploit vagally mediated satiety signals to re-
duce food intake [104] and have been recently approved by
the FDA. While these less invasive approaches are more
easily reversible and less likely to cause long-term com-
plications than bariatric surgery, they can be performed
only in specialist centres; consequently, the continued role
of pharmacotherapy in weight management is assured.
8 Conclusion
The past few years have witnessed the introduction of
novel anti-obesity therapies for the first time in over a
decade. Some represent refinements of older agents, some
are rationally devised combinations, and some are entirely
new approaches. Advancing understanding of energy
homeostatic mechanisms has been essential to signposting
development and continues to provide novel pharmaco-
logical targets yet to be exploited. However, our knowl-
edge of the off-target effects of some of these agents
remains incomplete, with outstanding safety concerns
leading to disagreement between the major regulatory
bodies regarding whether to grant approval. Research
should focus on understanding the potential for adverse
effects, not just the primary therapeutic aim. It remains to
be seen whether medical therapy can achieve the robust
The New Era of Drug Therapy for Obesity
weight loss of bariatric surgery. Currently, approved
weight loss medications are not licensed for use in com-
bination (apart from the fact that some are already poly-
therapies). Given the multiplicity of pathways regulating
food intake and energy expenditure, however, it may be
that combination therapy with more than one agent, pos-
sibly at lower doses than those licensed at present, will be a
viable treatment strategy to safely maximize weight loss in
the future.
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